Prostate Cancer News Adding talazoparib to first-line treatment with enzalutamide improves rPFS in patients with HRR-deficient mCRPC, a phase 3 trial suggests.
The approval was based on data from the phase 3 PROpel trial.
The approval was based on data from the LIGHTHOUSE and SPOTLIGHT trials.
Prostate cancer patients treated with second-generation antiandrogens may have an increased risk of falls, fatigue, and cognitive toxicity.
Study findings highlight the need for earlier mCSPC treatment intensification by urologists and oncologists.
The phase 3 EMBARK trial involved more than 200 global sites and had 8 years of follow-up.
Cancer death rates in the US have declined in recent years, but the declines vary by congressional district, a study suggests.
Adding 6 months of ADT to dose-escalated RT does not improve overall survival but does reduce prostate cancer-specific death, a study suggests.
New research indicates that prostate cancer among transgender women is not as rare as previous case reports suggest.
Patients with localized prostate cancer may face substantial out-of-pocket expenses up to 24 months after diagnosis, a survey suggests.
Patients diagnosed with prostate cancer during the first year of the COVID-19 pandemic were more likely to have higher-risk disease and less likely to receive definitive treatment.
Men with oligometastatic castration-sensitive prostate cancer have improved outcomes when ADT is added to MDT.
Patients with locally advanced and low metastatic burden prostate cancer have similar oncologic outcomes when treated with ADT alone.
Patients with localized prostate cancer have similar cancer-specific mortality whether they undergo surveillance, surgery, or radiotherapy, a study suggests.
A recent study revealed a racial disparity in the use of guideline-concordant treatment for metastatic prostate cancer.
Researchers say they have identified 4 subtypes of prostate cancer with distinct biological and clinical features, and these subtypes may respond differently to treatment.
Combining camonsertib with PARP inhibitors may be an effective strategy for treating advanced solid tumors, a study suggests.
Men aged 70 years or older continue to be screened for prostate cancer despite USPSTF recommendations against it.
Adding MDT to intermittent hormone therapy improves disease control in oligometastatic prostate cancer, a phase 2 trial suggests.
As many as 1 in 4 patients receiving treatment for cancer and HIV may be at risk of experiencing drug-drug interactions, according to researchers.
Load More